1332527-04-4

Basic information

• Product Name: 6-Bromo-3-methylsulfanyl-1-phenyl-1H-indazole
• Synonyms: 6-Bromo-3-methylsulfanyl-1-phenyl-1H-indazole
• CAS NO: 1332527-04-4
• Molecular Weight: 319.225
• Mol File: 1332527-04-4.mol

Chemical Properties

• CAS DataBase Reference: 6-Bromo-3-methylsulfanyl-1-phenyl-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-3-methylsulfanyl-1-phenyl-1H-indazole(1332527-04-4)
• EPA Substance Registry System: 6-Bromo-3-methylsulfanyl-1-phenyl-1H-indazole(1332527-04-4)

Safety Data

• Hazardous Substances Data: 1332527-04-4(Hazardous Substances Data)

Upstream product

• 1345403-94-2 2-Amino-4-bromo-benzoic acid N'-phenyl-hydrazide 
• 20776-50-5 2-amino-4-bromobenzoic acid 
• 1345403-95-3 6-bromo-1-phenyl-1H-indazole-3-thiol 
• 74-88-4 methyl iodide 
• 100-63-0 phenylhydrazine 
• 76561-16-5 7-bromo-1,2-dihydro-3,1-4H-benzoxazine-2,4-dione 
• 1345403-95-3 C₁₃H₉BrN₂S 
• 1332526-99-4 6-Bromo-1-phenyl-1,2-dihydro-indazol-3-one 

Downstream Products

• 1332526-60-9 3-methylsulfanyl-1-phenyl-6-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indazole 
• 1332526-61-0 3-methylsulfanyl-1-phenyl-6-(pyridin-4-yl)-1H-indazole 
• 1345403-96-4 4-(3-Methylsulfanyl-1-phenyl-1H-indazol-6-yl)-piperazine-1-carboxylic acid tert-butyl ester 
• 1345404-13-8 4-[1-(3-Methylsulfanyl-1-phenyl-1H-indazol-6-yl)-azetidin-3-yl]-piperazine-1-carboxylic acid tert-butyl ester 
• 1345404-16-1 (4-(3-(methylthio)-1-phenyl-1H-indazol-6-yl)piperazin-1-yl)(pyridin-4-yl)methanone 
• 1345404-15-0 3-[4-(3-Methylsulfanyl-1-phenyl-1H-indazol-6-yl)-piperazine-1-carbonyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1345403-93-1 3-(methylsulfanyl)-1-phenyl-6-piperazin-1-yl-1H-indazole hydrochloride 

Relevant articles and documents

INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS

The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.

Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors

A series of indazoles have been discovered as KHK inhibitors from a pyrazole hit identified through fragment-based drug discovery (FBDD). The optimization process guided by both X-ray crystallography and solution activity resulted in lead-like compounds with good pharmaceutical properties.